Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.
Y-HEP Health Center | Jonathan Lax Health Center
The following clinical trials are ongoing at the Lax Center and currently enrolling patients:
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alafenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed [SOLAR]
Description: The purpose of this study is to compare a newly approved combination anti-retroviral therapy administered every 2 months by injection to the current, oral standard of care. Please call 215-344-1631 or email research@fight.org if you are interested.
BEAT-HIV Delaney Collaboroatory
Are you interested in HIV cure-directed research? The Philadelphia based BEAT-HIV Delaney Collaboroatory is a group of more than 60 of the top HIV scientists from around the world working to advance the HIV cure research agenda. To get involved in an HIV cure-directed research trial, please call Linden Lalley-Chareczko, Research Program Director, at 215-344-1631.
The following clinical trials are ongoing at the Lax Center but are NOT enrolling new patients:
Open-label study to evaluate switching from a regimen of two NRTIs plus a third agent to a fixed dose combination of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected, African American participantsTrial number: GS-US-380-4580 Description: A phase 3b, open-label study to evaluate switching from a regimen of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus a third agent to a fixed dose combination (FDC) of bectegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed, HIV-1 infected, African American participants. |
Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis (PrEP)Trial Number: GS-US-412-2055 Description: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women who have Sex with Men and are at Risk of HIV-1 Infection |
Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Triumeq in HIV+, Treatment-Naïve AdultsTrial Number: GS-US-380-1489 Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 infected, antiretroviral treatment-naïve adults |
Randomized, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed [TANGO]Trial Number: 204862 Description: A phase 3, randomized study aiming to determine the efficacy, safety and tolerability of two approved medicines, dolutegravir (DTG) plus lamivudine (3TC) taken together, compared with subjects taking their current tenofovir alafenamide (TAF)-based regimen (TBR) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed. |
Switch Study to Evaluate D/C/F/TAF, Once-Daily versus Staying on a Boosted Protease Inhibitor RegimenTrial Number: TMC114IFD3013 |
The Immunopathogenisis of HIVDescription: Sponsored by The Wistar Institute |
The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:
| There are currently no trials enrolling at YHEP Health Center. Please check back soon! |
For more information on any of the clinical trials listed, please contact the Research Department at 215-525-8695.